12:31 PM EDT, 05/31/2024 (MT Newswires) -- Valneva SE ( VALN ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the issuance of a marketing authorization for the company's single-dose chikungunya vaccine IXCHIQ for individuals 18 years and older.

The European Commission will review the recommendation and is expected to make a final decision in Q3, Valneva said, adding it was preparing to apply for marketing authorization in the UK.

The vaccine was approved in the US in November. It is also under review in Canada and Brazil, with potential approvals expected this year, the company said.

Price: 9.09, Change: +0.19, Percent Change: +2.12